Autologous Cell Therapy-South America Market Status and Trend Report 2013-2023
![](/report_cover/10724/autologous-cell-therapy-south-america-market-status-n-trend-report-2013-2023_en.gif)
Report Summary
Autologous Cell Therapy-South America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Autologous Cell Therapy industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole South America and Regional Market Size of Autologous Cell Therapy 2013-2017, and development forecast 2018-2023
Main market players of Autologous Cell Therapy in South America, with company and product introduction, position in the Autologous Cell Therapy market
Market status and development trend of Autologous Cell Therapy by types and applications
Cost and profit status of Autologous Cell Therapy, and marketing status
Market growth drivers and challenges
The report segments the South America Autologous Cell Therapy market as:
South America Autologous Cell Therapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Brazil
Argentina
Venezuela
Colombia
Others
South America Autologous Cell Therapy Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Bone Marrow
Epidermis
South America Autologous Cell Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Neurology
Orthopedics
Cancer
Wound Healing
CVD
Autoimmune
Others
South America Autologous Cell Therapy Market: Players Segment Analysis (Company and Product introduction, Autologous Cell Therapy Sales Volume, Revenue, Price and Gross Margin):
BioTime, Inc.
BrainStorm Cell Therapeutics
Caladrius Biosciences, Inc.
Fibrocell Science, Inc.
Opexa Therapeutics, Inc.
Pharmicell Co., Inc.
Regeneus Ltd.
TiGenix NV
TxCell SA
U.S. Stem Cell, Inc.
Vericel Corporation
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Autologous Cell Therapy-South America Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Autologous Cell Therapy industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole South America and Regional Market Size of Autologous Cell Therapy 2013-2017, and development forecast 2018-2023
Main market players of Autologous Cell Therapy in South America, with company and product introduction, position in the Autologous Cell Therapy market
Market status and development trend of Autologous Cell Therapy by types and applications
Cost and profit status of Autologous Cell Therapy, and marketing status
Market growth drivers and challenges
The report segments the South America Autologous Cell Therapy market as:
South America Autologous Cell Therapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Brazil
Argentina
Venezuela
Colombia
Others
South America Autologous Cell Therapy Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Bone Marrow
Epidermis
South America Autologous Cell Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Neurology
Orthopedics
Cancer
Wound Healing
CVD
Autoimmune
Others
South America Autologous Cell Therapy Market: Players Segment Analysis (Company and Product introduction, Autologous Cell Therapy Sales Volume, Revenue, Price and Gross Margin):
BioTime, Inc.
BrainStorm Cell Therapeutics
Caladrius Biosciences, Inc.
Fibrocell Science, Inc.
Opexa Therapeutics, Inc.
Pharmicell Co., Inc.
Regeneus Ltd.
TiGenix NV
TxCell SA
U.S. Stem Cell, Inc.
Vericel Corporation
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF AUTOLOGOUS CELL THERAPY
1.1 Definition of Autologous Cell Therapy in This Report
1.2 Commercial Types of Autologous Cell Therapy
1.2.1 Bone Marrow
1.2.2 Epidermis
1.3 Downstream Application of Autologous Cell Therapy
1.3.1 Neurology
1.3.2 Orthopedics
1.3.3 Cancer
1.3.4 Wound Healing
1.3.5 CVD
1.3.6 Autoimmune
1.3.7 Others
1.4 Development History of Autologous Cell Therapy
1.5 Market Status and Trend of Autologous Cell Therapy 2013-2023
1.5.1 South America Autologous Cell Therapy Market Status and Trend 2013-2023
1.5.2 Regional Autologous Cell Therapy Market Status and Trend 2013-2023
CHAPTER 2 SOUTH AMERICA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Autologous Cell Therapy in South America 2013-2017
2.2 Consumption Market of Autologous Cell Therapy in South America by Regions
2.2.1 Consumption Volume of Autologous Cell Therapy in South America by Regions
2.2.2 Revenue of Autologous Cell Therapy in South America by Regions
2.3 Market Analysis of Autologous Cell Therapy in South America by Regions
2.3.1 Market Analysis of Autologous Cell Therapy in Brazil 2013-2017
2.3.2 Market Analysis of Autologous Cell Therapy in Argentina 2013-2017
2.3.3 Market Analysis of Autologous Cell Therapy in Venezuela 2013-2017
2.3.4 Market Analysis of Autologous Cell Therapy in Colombia 2013-2017
2.3.5 Market Analysis of Autologous Cell Therapy in Others 2013-2017
2.4 Market Development Forecast of Autologous Cell Therapy in South America 2018-2023
2.4.1 Market Development Forecast of Autologous Cell Therapy in South America 2018-2023
2.4.2 Market Development Forecast of Autologous Cell Therapy by Regions 2018-2023
CHAPTER 3 SOUTH AMERICA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole South America Market Status by Types
3.1.1 Consumption Volume of Autologous Cell Therapy in South America by Types
3.1.2 Revenue of Autologous Cell Therapy in South America by Types
3.2 South America Market Status by Types in Major Countries
3.2.1 Market Status by Types in Brazil
3.2.2 Market Status by Types in Argentina
3.2.3 Market Status by Types in Venezuela
3.2.4 Market Status by Types in Colombia
3.2.5 Market Status by Types in Others
3.3 Market Forecast of Autologous Cell Therapy in South America by Types
CHAPTER 4 SOUTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Autologous Cell Therapy in South America by Downstream Industry
4.2 Demand Volume of Autologous Cell Therapy by Downstream Industry in Major Countries
4.2.1 Demand Volume of Autologous Cell Therapy by Downstream Industry in Brazil
4.2.2 Demand Volume of Autologous Cell Therapy by Downstream Industry in Argentina
4.2.3 Demand Volume of Autologous Cell Therapy by Downstream Industry in Venezuela
4.2.4 Demand Volume of Autologous Cell Therapy by Downstream Industry in Colombia
4.2.5 Demand Volume of Autologous Cell Therapy by Downstream Industry in Others
4.3 Market Forecast of Autologous Cell Therapy in South America by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF AUTOLOGOUS CELL THERAPY
5.1 South America Economy Situation and Trend Overview
5.2 Autologous Cell Therapy Downstream Industry Situation and Trend Overview
CHAPTER 6 AUTOLOGOUS CELL THERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN SOUTH AMERICA
6.1 Sales Volume of Autologous Cell Therapy in South America by Major Players
6.2 Revenue of Autologous Cell Therapy in South America by Major Players
6.3 Basic Information of Autologous Cell Therapy by Major Players
6.3.1 Headquarters Location and Established Time of Autologous Cell Therapy Major Players
6.3.2 Employees and Revenue Level of Autologous Cell Therapy Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 AUTOLOGOUS CELL THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 BioTime, Inc.
7.1.1 Company profile
7.1.2 Representative Autologous Cell Therapy Product
7.1.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of BioTime, Inc.
7.2 BrainStorm Cell Therapeutics
7.2.1 Company profile
7.2.2 Representative Autologous Cell Therapy Product
7.2.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of BrainStorm Cell Therapeutics
7.3 Caladrius Biosciences, Inc.
7.3.1 Company profile
7.3.2 Representative Autologous Cell Therapy Product
7.3.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Caladrius Biosciences, Inc.
7.4 Fibrocell Science, Inc.
7.4.1 Company profile
7.4.2 Representative Autologous Cell Therapy Product
7.4.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Fibrocell Science, Inc.
7.5 Opexa Therapeutics, Inc.
7.5.1 Company profile
7.5.2 Representative Autologous Cell Therapy Product
7.5.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Opexa Therapeutics, Inc.
7.6 Pharmicell Co., Inc.
7.6.1 Company profile
7.6.2 Representative Autologous Cell Therapy Product
7.6.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Pharmicell Co., Inc.
7.7 Regeneus Ltd.
7.7.1 Company profile
7.7.2 Representative Autologous Cell Therapy Product
7.7.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Regeneus Ltd.
7.8 TiGenix NV
7.8.1 Company profile
7.8.2 Representative Autologous Cell Therapy Product
7.8.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of TiGenix NV
7.9 TxCell SA
7.9.1 Company profile
7.9.2 Representative Autologous Cell Therapy Product
7.9.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of TxCell SA
7.10 U.S. Stem Cell, Inc.
7.10.1 Company profile
7.10.2 Representative Autologous Cell Therapy Product
7.10.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of U.S. Stem Cell, Inc.
7.11 Vericel Corporation
7.11.1 Company profile
7.11.2 Representative Autologous Cell Therapy Product
7.11.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Vericel Corporation
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF AUTOLOGOUS CELL THERAPY
8.1 Industry Chain of Autologous Cell Therapy
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF AUTOLOGOUS CELL THERAPY
9.1 Cost Structure Analysis of Autologous Cell Therapy
9.2 Raw Materials Cost Analysis of Autologous Cell Therapy
9.3 Labor Cost Analysis of Autologous Cell Therapy
9.4 Manufacturing Expenses Analysis of Autologous Cell Therapy
CHAPTER 10 MARKETING STATUS ANALYSIS OF AUTOLOGOUS CELL THERAPY
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Autologous Cell Therapy in This Report
1.2 Commercial Types of Autologous Cell Therapy
1.2.1 Bone Marrow
1.2.2 Epidermis
1.3 Downstream Application of Autologous Cell Therapy
1.3.1 Neurology
1.3.2 Orthopedics
1.3.3 Cancer
1.3.4 Wound Healing
1.3.5 CVD
1.3.6 Autoimmune
1.3.7 Others
1.4 Development History of Autologous Cell Therapy
1.5 Market Status and Trend of Autologous Cell Therapy 2013-2023
1.5.1 South America Autologous Cell Therapy Market Status and Trend 2013-2023
1.5.2 Regional Autologous Cell Therapy Market Status and Trend 2013-2023
CHAPTER 2 SOUTH AMERICA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Autologous Cell Therapy in South America 2013-2017
2.2 Consumption Market of Autologous Cell Therapy in South America by Regions
2.2.1 Consumption Volume of Autologous Cell Therapy in South America by Regions
2.2.2 Revenue of Autologous Cell Therapy in South America by Regions
2.3 Market Analysis of Autologous Cell Therapy in South America by Regions
2.3.1 Market Analysis of Autologous Cell Therapy in Brazil 2013-2017
2.3.2 Market Analysis of Autologous Cell Therapy in Argentina 2013-2017
2.3.3 Market Analysis of Autologous Cell Therapy in Venezuela 2013-2017
2.3.4 Market Analysis of Autologous Cell Therapy in Colombia 2013-2017
2.3.5 Market Analysis of Autologous Cell Therapy in Others 2013-2017
2.4 Market Development Forecast of Autologous Cell Therapy in South America 2018-2023
2.4.1 Market Development Forecast of Autologous Cell Therapy in South America 2018-2023
2.4.2 Market Development Forecast of Autologous Cell Therapy by Regions 2018-2023
CHAPTER 3 SOUTH AMERICA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole South America Market Status by Types
3.1.1 Consumption Volume of Autologous Cell Therapy in South America by Types
3.1.2 Revenue of Autologous Cell Therapy in South America by Types
3.2 South America Market Status by Types in Major Countries
3.2.1 Market Status by Types in Brazil
3.2.2 Market Status by Types in Argentina
3.2.3 Market Status by Types in Venezuela
3.2.4 Market Status by Types in Colombia
3.2.5 Market Status by Types in Others
3.3 Market Forecast of Autologous Cell Therapy in South America by Types
CHAPTER 4 SOUTH AMERICA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Autologous Cell Therapy in South America by Downstream Industry
4.2 Demand Volume of Autologous Cell Therapy by Downstream Industry in Major Countries
4.2.1 Demand Volume of Autologous Cell Therapy by Downstream Industry in Brazil
4.2.2 Demand Volume of Autologous Cell Therapy by Downstream Industry in Argentina
4.2.3 Demand Volume of Autologous Cell Therapy by Downstream Industry in Venezuela
4.2.4 Demand Volume of Autologous Cell Therapy by Downstream Industry in Colombia
4.2.5 Demand Volume of Autologous Cell Therapy by Downstream Industry in Others
4.3 Market Forecast of Autologous Cell Therapy in South America by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF AUTOLOGOUS CELL THERAPY
5.1 South America Economy Situation and Trend Overview
5.2 Autologous Cell Therapy Downstream Industry Situation and Trend Overview
CHAPTER 6 AUTOLOGOUS CELL THERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN SOUTH AMERICA
6.1 Sales Volume of Autologous Cell Therapy in South America by Major Players
6.2 Revenue of Autologous Cell Therapy in South America by Major Players
6.3 Basic Information of Autologous Cell Therapy by Major Players
6.3.1 Headquarters Location and Established Time of Autologous Cell Therapy Major Players
6.3.2 Employees and Revenue Level of Autologous Cell Therapy Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 AUTOLOGOUS CELL THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 BioTime, Inc.
7.1.1 Company profile
7.1.2 Representative Autologous Cell Therapy Product
7.1.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of BioTime, Inc.
7.2 BrainStorm Cell Therapeutics
7.2.1 Company profile
7.2.2 Representative Autologous Cell Therapy Product
7.2.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of BrainStorm Cell Therapeutics
7.3 Caladrius Biosciences, Inc.
7.3.1 Company profile
7.3.2 Representative Autologous Cell Therapy Product
7.3.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Caladrius Biosciences, Inc.
7.4 Fibrocell Science, Inc.
7.4.1 Company profile
7.4.2 Representative Autologous Cell Therapy Product
7.4.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Fibrocell Science, Inc.
7.5 Opexa Therapeutics, Inc.
7.5.1 Company profile
7.5.2 Representative Autologous Cell Therapy Product
7.5.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Opexa Therapeutics, Inc.
7.6 Pharmicell Co., Inc.
7.6.1 Company profile
7.6.2 Representative Autologous Cell Therapy Product
7.6.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Pharmicell Co., Inc.
7.7 Regeneus Ltd.
7.7.1 Company profile
7.7.2 Representative Autologous Cell Therapy Product
7.7.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Regeneus Ltd.
7.8 TiGenix NV
7.8.1 Company profile
7.8.2 Representative Autologous Cell Therapy Product
7.8.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of TiGenix NV
7.9 TxCell SA
7.9.1 Company profile
7.9.2 Representative Autologous Cell Therapy Product
7.9.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of TxCell SA
7.10 U.S. Stem Cell, Inc.
7.10.1 Company profile
7.10.2 Representative Autologous Cell Therapy Product
7.10.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of U.S. Stem Cell, Inc.
7.11 Vericel Corporation
7.11.1 Company profile
7.11.2 Representative Autologous Cell Therapy Product
7.11.3 Autologous Cell Therapy Sales, Revenue, Price and Gross Margin of Vericel Corporation
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF AUTOLOGOUS CELL THERAPY
8.1 Industry Chain of Autologous Cell Therapy
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF AUTOLOGOUS CELL THERAPY
9.1 Cost Structure Analysis of Autologous Cell Therapy
9.2 Raw Materials Cost Analysis of Autologous Cell Therapy
9.3 Labor Cost Analysis of Autologous Cell Therapy
9.4 Manufacturing Expenses Analysis of Autologous Cell Therapy
CHAPTER 10 MARKETING STATUS ANALYSIS OF AUTOLOGOUS CELL THERAPY
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference